Eugene Melnyk news from FierceBiotech
News
Melnyk outlines $100M blueprint for new developer
Fresh from losing an insurgent attack aimed at winning back control of Biovail, the Canadian entrepreneur says he plans to invest $50 million to $100 million of his own money to start a new R&D Read more...
Biovail focuses on CNS drugs
As the battle for Biovail continues, current CEO William Wells emphasized the company's focus on CNS drug development at Goldman Sachs' annual healthcare conference. Biovail is investing $600 million Read more...
ALSO NOTED: Acorda shares soar; Lexicon wins fast track; NIH grants $533N in research funds; and much more...
> News yesterday that Acorda Therapeutics' experimental MS drug helped patients walk better sent its shares up 27 percent. Read more...
Biovail picks Wells as CEO
Canadian drugmaker Biovail has named a new chief to take the reigns from interim CEO Douglas Squires. William Wells has been appointed Biovail's new CEO, effective May 1, 2008. He's been on the Read more...
ALSO NOTED: Analysts offer conflicting forecasts for Auxilium; test sheds light on cancer therapy; MAP touts new data; and much
> Two analysts assessed Auxilium Pharmaceuticals' chances in a late-stage study of Xiaflex and came up with radically different conclusions. Data is expected in the second quarter. Read more...
Melnyk slams Biovail board, calls for change
Biovail founder--and largest shareholder--Eugene Melnyk (photo) isn't happy with the company's management, and he's going to do something about it. Read more...
Get more Eugene Melnyk coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets